{"id":53937,"date":"2021-07-07T12:08:34","date_gmt":"2021-07-07T12:08:34","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=76095"},"modified":"2021-07-07T12:08:34","modified_gmt":"2021-07-07T12:08:34","slug":"gt-biopharma-announces-sponsored-research-agreement-with-dr-jeffrey-s-miller-of-the-university-of-minnesota","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-announces-sponsored-research-agreement-with-dr-jeffrey-s-miller-of-the-university-of-minnesota\/","title":{"rendered":"GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota"},"content":{"rendered":"
\n
\n
\n

Deepening relationship between GT Biopharma and Dr. Jeffrey Miller <\/i> <\/b><\/p>\n

TriKE\u2122 improves FT538 iPSC NK cells from Fate Therapeutics in prostate cancer model<\/i> <\/b><\/p>\n

GTB-3550 continues to demonstrate clinical success without significant toxicities<\/i> <\/b><\/p>\n

BEVERLY HILLS, Calif., July 7, 2021 \/PRNewswire\/ —\u00a0GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE\u2122) protein biologic technology platform, announced it has entered into a sponsored research agreement (SRA) with Jeffrey S. Miller, M.D., Deputy Director of the University of Minnesota’s Masonic Cancer Center and Consulting Chief Scientific Officer of GT Biopharma.<\/p>\n

\"GT<\/div>\n

The SRA is focused on supporting GT Biopharma’s continued clinical develop of TriKE\u2122 therapeutic product candidates, and to gain an increased understanding of changes in the patient’s native NK cell population as a result of TriKE\u2122 therapy. The SRA is a fixed sum contract worth Two Million Seventy-Four Thousand Six Hundred Eighty-Six dollars ($2,074,686) payable over the next two years in equal quarterly payments. GT Biopharma has early termination rights without financial penalty, and will receive an exclusive worldwide license to any patentable inventions which arise under the SRA.<\/p>\n

TriKE\u2122 is a robust and versatile protein biologic therapeutic platform which facilitates NK recognition and killing of cancer cells. TriKE\u2122 is a tri-specific recombinant protein biologic composed of an NK cell engaging domain targeting CD16 on the NK cell, an NK cell activating domain consisting Interleukin IL-15, and a cancer cell targeting domain. The natural killer (NK) cell-stimulating cytokine human IL-15 portion of the molecule provides a self-sustaining signal that activates the patient’s endogenous, exhausted\/inhibited NK cells enhancing their ability to kill and proliferate without the need for the supplemental addition of ex vivo<\/i> engineered NK cells. TriKE\u2122 does not require costly or specialized manufacturing facilities nor is pretreatment of the patient required prior to its administration. TriKE\u2122 is also significantly less expensive than iPSC NK cell therapies and autologous\/allogenic NK cell therapies.<\/p>\n

Recently published data at the November 2020 meeting of the Society for Immunotherapy of Cancer (SITC) by researchers at Fate Therapeutics and the University of Minnesota (see https:\/\/jitc.bmj.com\/content\/8\/Suppl_3\/A287<\/a>) demonstrates TriKE\u2122 is able to activate and target direct Fate Therapeutics’ ex vivo<\/i> engineered iPSC NK cells (FT538), and turn those cells into more effective killers resulting in the complete eradication of the prostate cancer cells. Without the assistance of TriKE\u2122, the FT538 iPSC NK cells were unable to eradicate the prostate cancer cells.<\/p>\n

TriKE\u2122 monotherapy has demonstrated in its first-in-class clinical trial the ability to revive the patient’s exhausted\/inhibited NK cells, significantly reduce cancer cell numbers, and to do so without any toxicities including no cytokine release syndrome (CRS). Highlights to date from patients treated with GTB-3550 TriKE\u2122 monotherapy in the dose escalation Phase 1 clinical trial for the treatment of high-risk MDS and refractory\/relapsed AML:<\/p>\n